Overview

Treatment Effect According to Timing of Administration of DWP14012 40 mg

Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
0
Participant gender:
All
Summary
The primary objective of this study is to establish noninferiority of efficacy of DWP14012 (40 mg once daily) based on Timing of Administration.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Konkuk University Medical Center
Collaborator:
Daewoong Pharmaceutical Co. LTD.
Criteria
Inclusion Criteria:

- Adults between 19 and 75 years old based on the date of written agreement

- Those who have been diagnosed with erosive esophagitis of LA Grade A-D on the upper
gastrointestinal endoscopy

- Those who experienced symptoms of heartburn or acid regurgitation within the last 7
days

Exclusion Criteria:

- Those who have undergone gastric acid suppression or gastric, esophageal surgery

- Those who with clinically significant liver, kidney, nervous system, respiratory,
endocrine, hematologic, cardiovascular, urinary system disease